Boothbay Fund Management’s Vir Biotechnology VIR Stock Holding History

Boothbay Fund Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-63,227	Closed	-$567K	–	2662
2026 Q1	$567K	Sell	63,227 -72,474	-53%	-$577K	0.01%	1272
2025 Q4	$818K	Sell	135,701 -22,422	-14%	-$134K	0.01%	884
2025 Q3	$903K	Sell	158,123 -148,422	-48%	-$759K	0.01%	869
2025 Q2	$1.54M	Hold	306,545	–	–	0.03%	560
2025 Q1	$1.99M	Buy	306,545 +46,174	+18%	+$411K	0.05%	430
2024 Q4	$1.91M	Buy	+260,371	New	+$2.05M	0.05%	459
2022 Q2	–	Sell	-47,789	Closed	-$1.23M	–	2698
2022 Q1	$1.23M	Buy	+47,789	New	+$1.42M	0.03%	802
2020 Q3	–	Sell	-10,100	Closed	-$414K	–	1233
2020 Q2	$414K	Buy	+10,100	New	+$339K	0.03%	626

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Boothbay Fund Management's VIR Position: Q2 2026 in Review

Boothbay Fund Management sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 63,227 shares — an estimated $567K sold.

Boothbay Fund Management first reported a position in VIR in Q2 2020 and held it in 8 quarters. The position peaked at $1.99M in Q1 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Boothbay Fund Management reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 63,227 Vir Biotechnology shares in Q2 2026, an estimated $567K.
Boothbay Fund Management first reported a position in Vir Biotechnology in Q2 2020 and held it in 8 quarters.
Boothbay Fund Management's Vir Biotechnology position peaked at $1.99M in Q1 2025.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.